en · de · es · pt
cardarine-notes.peptides6823.com › Data › Mechanism And Safety Research — Reference Sheet

Mechanism And Safety Research — Reference Sheet

By Editorial Desk · published 2025-09-13 · last reviewed 2025-11-05 · Data

This is a working overview of Cardarine, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-11-05 and is reviewed periodically as new material appears.

Mechanism and Safety Research

Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.

Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.

GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.

Regulatory Status and Detection Context

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδNuclear receptor; not androgen receptor
Studied indicationsDyslipidemia; obesity; diabetesEarly clinical research; development discontinued
Rodent toxicityTumor formation in multiple tissuesDose-dependent findings in some studies
Human approvalNoneNo approved therapeutic use
Typical analytical methodLC-MS/MSUsed for identity and quantification

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.

Related pages on this site

Identity and Regulatory Status

Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Detection and Regulatory Landscape

Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.

A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.

Supporting material

On 7 September 2020, CSL signed agreements with the Australian government to supply the University of Queensland vaccine (V451) and to manufacture (with AstraZeneca) the Oxford University vaccine (AZD1222), which would yield nearly 85 million doses for Australians. The agreement was contingent on the future success of clinical trials of these vaccines. Most of the manufacture would occur in Melbourne, Australia. On 11 December 2020, after a high percentage of the University of Queensland vaccine trial participants returned "false positive" results for HIV, it was decided that vaccine development will not proceed to Phase 2/3 trials. On 23 March 2021, the Therapeutic Goods Administration provisionally approved the first batches, numbering 832,000 doses, of the Oxford–AstraZeneca COVID-19 vaccine manufactured by CSL in its plant in Broadmeadows, Victoria. The Australian Government has contracted CSL to produce 50 million doses of the vaccine.

Australia Australian Border Force Brunei Department of Immigration and National Registration Royal Customs and Excise Department Canada Immigration, Refugees and Citizenship Canada Canada Border Services Agency (previously Canada Customs and Revenue Agency) Canadian Air Transport Security Authority China National Immigration Administration of Ministry of Public Security People's Armed Police General Administration of Customs Immigration Department (Hong Kong) Hong Kong Customs and Excise Department Public Security Police Force of Macau Macau Customs Service India Border Security Force The Assam Rifles Indo-Tibetan Border Police Indonesia Directorate General of Immigration (Indonesia) Directorate General of Customs and Excise Ireland Irish Naturalisation and Immigration Service Garda National Immigration Bureau Revenue Commissioners Iran The Immigration & Passport Police Office, a subdivision of Law Enforcement Force of Islamic Republic of Iran Islamic Republic of Iran Border Guard Command ("NAJA Border Guard"), a subdivision of Law Enforcement Force of Islamic Republic of Iran Malaysia Immigration Department of Malaysia Royal Malaysian Customs Department North Korea Border Security Command Coastal Security Bureau Pakistan Pakistan Rangers Frontier Corps Gilgit−Baltistan Scouts Pakistan Army Pakistan Rangers Pakistan Customs Philippines Bureau of Customs Bureau of Immigration Schengen Area European Border and Coast Guard Agency (Frontex) France Direction centrale de la police aux frontières (a directorate of the French National Police) Direction générale des douanes et droits indirects (DGDDI) Finland Finnish Border Guard Finnish Customs Germany Federal Police Bundeszollverwaltung Italy Polizia di Stato Guardia di Finanza Arma dei Carabinieri Netherlands Koninklijke Marechaussee (English: Royal Military Constabulary), a branch of the Dutch Armed Forces Fiscal Information and Investigation Service New Zealand New Zealand Immigration New Zealand Customs Service Norway Norwegian Police Service Norwegian Customs Service Ranger Battalion GSV (only between Norway and Russia) Spain Cuerpo Nacional de Policía Guardia Civil Customs Surveillance Service Switzerland Federal Department of Justice and Police Federal Office of Police Federal Department of Finance Swiss Border Guard Sweden Swedish Border Police South Korea Korean Immigration Service, Ministry of Justice Korea Customs Service Singapore Immigration and Checkpoints Authority Singapore Customs Taiwan National Immigration Agency Customs Administration Thailand Thai Immigration Department Thai Customs United Kingdom HM Revenue and Customs UK Border Force Immigration Enforcement United States Department of Homeland Security (DHS) U.S. Customs and Border Protection (CBP), a division of the DHS United States Border Patrol Transportation Security Administration U.S. Immigration and Customs Enforcement, or ICE United States Citizenship and Immigration Services Vietnam Vietnam Immigration Department Vietnam Customs

One of the most acutely toxic indoor air contaminants is carbon monoxide (CO), a colorless and odorless gas that is a by-product of incomplete combustion. Carbon monoxide may be emitted from tobacco smoke and generated from malfunctioning fuel burning stoves (wood, kerosene, natural gas, propane) and fuel burning heating systems (wood, oil, natural gas) and from blocked flues connected to these appliances. In developed countries the main sources of indoor CO emission come from cooking and heating devices that burn fossil fuels and are faulty, incorrectly installed or poorly maintained. Appliance malfunction may be due to faulty installation or lack of maintenance and proper use. In low- and middle-income countries the most common sources of CO in homes are burning biomass fuels and cigarette smoke. Health effects of CO poisoning may be acute or chronic and can occur unintentionally or intentionally (self-harm). By depriving the brain of oxygen, acute exposure to carbon monoxide may have effects on the neurological system (headache, nausea, dizziness, alteration in consciousness and subjective weakness), the cardiovascular and respiratory systems (myocardial infarction, shortness of breath, or rapid breathing, respiratory failure). Acute exposure can also lead to long-term neurological effects such as cognitive and behavioral changes. Severe CO poisoning may lead to unconsciousness, coma and death. Chronic exposure to low concentrations of carbon monoxide may lead to lethargy, headaches, nausea, flu-like symptoms and neuropsychological and cardiovascular issues.

Sources: en.wikipedia.org

Notes from published material

Cèpe bronzé ("dark cep"; Boletus aereus), much rarer than B. edulis, is more highly regarded by gourmets and consequently more expensive. Usually smaller than B. edulis, it is also distinctively darker in colour. It is especially suited to drying. Cèpe des pins ("pine tree cep"; Boletus pinophilus or Boletus pinicola) grows among pine trees. Rarer than B. edulis, it is less appreciated by gourmets than the two other kinds of porcini, but remains a mushroom rated above most others. Cèpe d'été ("summer cep"; Boletus reticulatus), also less common and found earlier. Molecular phylogenetic analyses have proven these three are all distinctive and separate species; other taxa formerly believed to be unique species or subspecies, such as B. betulicola, B. chippewaensis, B. persoonii, B. quercicola and B. venturii, are now known to be part of a B. edulis species complex with a wide morphological, ecological and geographic range, and that the genetic variability in this complex is low. Similar molecular technology has been developed to rapidly and accurately identify B. edulis and other commercially important fungi. Three divergent lineages found in Yunnan province in China that are commonly marketed and sold as B. edulis (and are actually more closely related to B. aereus) were described in 2013 as B. bainiugan, B. meiweiniuganjun and B. shiyong. The classification has since been updated and expanded. All lineages are still members of Boletus sect. Boletus, the sensu stricto "porcini clade" of the genus.

== History == Experimentally the first examples of mechanically interlocked molecular architectures appeared in the 1960s with catenanes being synthesized by Wasserman and Schill and rotaxanes by Harrison and Harrison. The chemistry of MIMAs came of age when Sauvage pioneered their synthesis using templating methods. In the early 1990s the usefulness and even the existence of MIMAs were challenged. The latter concern was addressed by X ray crystallographer and structural chemist David Williams. Two postdoctoral researchers who took on the challenge of producing [5]catenane (olympiadane) pushed the boundaries of the complexity of MIMAs that could be synthesized their success was confirmed in 1996 by a solid‐state structure analysis conducted by David Williams.

=== Länder in East Germany === In the Soviet occupation zone, five Länder were established which roughly corresponded to the preexisting states and provinces. (The territories east of the Oder–Neisse line had been transferred from the Soviet occupation zone to the Polish authorities as agreed upon at the Potsdam Conference.) The five states were:

Thymopentin is a thymic polypeptide derivative which interacts with T cells and acts as an immunostimulant. As such, it was used in several clinical studies in the early years of the AIDS pandemic (from 1983 to 1985). Thymopentin helped to improve immunological condition in some patients for a brief time under specific treatments. It has also been investigated more recently for applications in the treatment of rheumatoid arthritis, and lung cancer.

Sources: en.wikipedia.org

Background from the literature

The enzyme is a cytochrome P450 protein containing heme, isolated from Rauvolfia species. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. The systematic name of this enzyme class is 10-deoxysarpagine,NADPH:oxygen oxidoreductase (10-hydroxylating). It is also called DOSH. The compounds are indole alkaloids.

The Australian Rugby League Commission Limited (ARL), formerly the Australian Rugby Football League Limited is an Australian rugby league football competition operator. It was founded in 1986 as the Australian Rugby Football League Limited and succeeded the Australian Rugby Football League Board of Control which had been formed in 1924. Since its inception, the ARL has administered the Australian national team and represented Australia in international rugby league matters. Prior to 1998, the code in Australia had been principally administered by individual state leagues on a domestic basis, and the ARL on a national and international basis.

=== Gluten-free === As buckwheat contains no gluten, it may be eaten by people with gluten-related disorders, such as celiac disease, non-celiac gluten sensitivity or dermatitis herpetiformis. Nevertheless, buckwheat products may have gluten contamination.

He attended college at University of California, Santa Cruz, for two years before transferring to New York University (NYU)'s Tisch School of the Arts, where he graduated in 2000. While at NYU, writer Murray Miller was his roommate.

The Socialist Republic of Serbia (SR Serbia), known from 1946 to 1963 as the People's Republic of Serbia and commonly referred to as Serbia, was one of the six constituent republics of the Socialist Federal Republic of Yugoslavia. Its formation was initiated in 1941, and achieved in 1944–1946, when it was established as a federated republic within Yugoslavia. In that form, it lasted until the constitutional reforms from 1990 to 1992, when it was reconstituted, as the Republic of Serbia within the Federal Republic of Yugoslavia. It was the largest constituent republic of Yugoslavia, in terms of population and territory. Within Serbia were the two autonomous provinces: Kosovo and Vojvodina. Its capital, Belgrade, was also the federal capital of Yugoslavia.

Sources: en.wikipedia.org

Frequently asked questions

What is the main molecular target of cardarine?

It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.

Why did development of GW501516 stop?

Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.

Does cardarine improve endurance in people?

Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.

Is cardarine approved for any medical use?

No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.

Network